ESMO 2024 Press Conference
WEBSep 13, 2024 · Emerging Approaches Central to Future Cancer Therapy. Date: 13 Sep 2024. The ESMO Congress 2024 will hold a press conference to introduce and discuss the “Eyes to the Future” Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer ...
Highlights from ESMO 2024: Key Oncology Advances from Major ...
WEB2 days ago · T he 2024 European Society for Medical Oncology (ESMO) Congress illuminated a range of transformative advances that are set to reshape the oncology field.This year’s event underscored the pivotal role of groundbreaking research and innovative treatments in advancing cancer care. Highlights included AbbVie’s updates on novel antibody-drug conjugates targeting ovarian cancer and c-Met ...
ESMO Congress 2024
WEBSep 13, 2024 · The ESMO Congress is a globally influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. ESMO 2024 disseminated the latest cutting-edge data, provided high quality education and excellent networking opportunities for oncologists and other ...
ESMO Congress 2024 - Daily Reporter
WEBSep 6, 2024 · Subscribe to the ESMO Daily Reporter Alert and find out the latest advances in cancer care with our news and interviews to international experts. To receive the alert on a regular basis, create or login to your ESMO account and opt-in. ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO.
ESMO Congress 2024 - Daily Reporter
WEBAdding durvalumab to neoadjuvant chemotherapy improves survival in muscle-invasive bladder cancer. Practice changing results of event-free survival and overall survival are reported from the NIAGARA study. 15 Sept 2024.
Promising antitumour activity for emerging targets - dailyreporter.esmo…
WEB5 days ago · At the ESMO Congress 2024 (Barcelona, 13–17 September), some early-phase trials described promising strategies to target emerging actionable mutations in different solid tumours, such as methylthioadenosine phosphorylase (MTAP) deletion, KRAS G12D mutation, and CDK4 and 2, reporting good tolerability and antitumour activity for novel targeted ...
ESMO 2024: breaking news and abstracts - Oncology Central
WEBWith ESMO 2024 (13–17 September, Barcelona, Spain) wrapped up, we're excited to bring you the latest breaking news, late-breaking abstracts and highlights from this year's congress. From groundbreaking trials to innovative research developments, this collection captures the most impactful moments.
ESMO 2024: Four Key Takeaways from Europe’s Biggest Oncology …
WEB2 days ago · Europe, ESMO, Cancer, Oncology, Immunotherapy, ADCs, AstraZeneca, MSD, Daiichi Sankyo. This year’s European Society of Medical Oncology (ESMO) was the largest ever. Over 33,000 people attended ESMO Congress 2024 at Barcelona’s cavernous Fira Gran Via conference centre, where 5,000 abstracts were presented and 600 expert speakers took to the ...
ESMO 2024: An immunotherapy milestone, studying young-onset …
WEB5 days ago · Sept. 16, 2024. Europe Correspondent. This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain ...
ESMO 2024: Pfizer’s cachexia drug provides meaningful weight gain
WEB5 days ago · Ross Law September 16, 2024. Ponsegromab achieved weight increase in all dose cohorts of Pfizer’s Phase II trial. Credit: Jonathan Weiss / Shutterstock. Pfizer ’s cancer cachexia candidate has provided patients with clinically meaningful weight gain in a Phase II trial, with the company sharing aims to start a pivotal programme in 2025.
- Some results have been removed